Financial Comparison: Windtree Therapeutics (OTCMKTS:WINT) vs. Gamida Cell (OTCMKTS:GMDA)
Windtree Therapeutics (OTCMKTS:WINT) and Gamida Cell (NASDAQ:GMDA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.
Earnings & Valuation
This table compares Windtree Therapeutics and Gamida Cell’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Windtree Therapeutics||$1.79 million||96.29||-$20.53 million||N/A||N/A|
|Gamida Cell||N/A||N/A||-$52.93 million||($10.53)||-0.43|
Insider and Institutional Ownership
23.9% of Gamida Cell shares are held by institutional investors. 14.9% of Windtree Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Windtree Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Gamida Cell has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.
This table compares Windtree Therapeutics and Gamida Cell’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings for Windtree Therapeutics and Gamida Cell, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Gamida Cell has a consensus target price of $17.67, indicating a potential upside of 289.13%. Given Gamida Cell’s higher probable upside, analysts plainly believe Gamida Cell is more favorable than Windtree Therapeutics.
Gamida Cell beats Windtree Therapeutics on 6 of the 11 factors compared between the two stocks.
About Windtree Therapeutics
Windtree Therapeutics, Inc., a biotechnology company, focuses on developing surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and drug-delivery technologies being developed to enable the noninvasive administration of aerosolized KL4 surfactant. The company's lead development program comprises AEROSURF, a drug/device product that has completed Phase IIb clinical trial to treat respiratory distress syndrome in premature infants. It is also developing other aerosolized KL4 surfactant products. Windtree Therapeutics, Inc. has a strategic collaboration with Eleison Pharmaceuticals, Inc. for using its proprietary aerosol delivery system to deliver inhaled lipid cisplatin in combination with KL4 surfactant. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
About Gamida Cell
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.